AGP Picks
View all

ExposeIQ adds human-verified jury simulation tools for medical malpractice cases

Jun. 29, 2026
By AI, Created 04:09 UTC, Jun 29, 2026, AGP -

ExposeIQ says its JuryFit platform is helping medical malpractice attorneys structure jury selection with human-verified profile analysis and virtual mirror jury simulations. The company is positioning the tool as decision support for complex cases where jurors must weigh technical evidence, expert testimony and damages.

Why it matters: - Medical malpractice trials often turn on jurors’ ability to process complex clinical evidence, standards of care and expert testimony. - ExposeIQ is pitching JuryFit as a way to reduce uncertainty in jury selection and help trial teams prepare for technically demanding cases. - The platform is intended as decision support, not a replacement for licensed attorneys’ independent judgment.

What happened: - ExposeIQ said JuryFit is helping attorneys build more structured approaches to jury selection in medical malpractice litigation. - JuryFit is part of ExposeIQ’s LENS trial intelligence suite. - The platform analyzes case narratives against 16 juror personality profiles. - Human verification is applied at each step, from identifying juror personality blends to qualifying Voir Dire questions. - The company says the process is designed to keep insights relevant and professionally grounded.

The details: - JuryFit’s Virtual Mirror Jury™ feature creates simulations based on seated jurors’ profiles. - Trial teams can use the simulations to rehearse arguments about medical standards, causation and damages. - The platform maps how different personality profiles may respond to medical terminology, expert credibility and negligence questions. - That analysis is used to tailor Voir Dire questions to the specific challenges of malpractice cases. - ExposeIQ said all platform outputs require independent review by licensed attorneys. - Results vary by matter. - ExposeIQ describes itself as a real-time litigation intelligence platform for high-stakes legal professionals. - The company says its LENS suite supports jury intelligence and trial preparation. - ExposeIQ says it is a technology company, not a law firm, and does not provide legal advice.

Between the lines: - The product push reflects growing demand for tools that complement traditional trial preparation in specialized, high-stakes practice areas. - The human-verification layer appears aimed at addressing skepticism around automated jury analytics by keeping attorneys in control of strategy. - The emphasis on simulations suggests ExposeIQ is selling not just data, but a rehearsal environment for high-pressure courtroom decisions.

What's next: - ExposeIQ is likely to continue positioning JuryFit as a support tool for litigation teams handling complex medical malpractice matters. - Attorneys using the platform will still need to validate outputs case by case before relying on them in jury selection. - The company’s social links include Joseph Terp’s LinkedIn profile and Joseph Terp’s X account.

Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.

Sign up for:

Today in Medicine

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

Today in Medicine

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.